On January 12, 2017, the U.S. Court of Appeals for the Federal Circuit issued an opinion affirming the judgement that Eli Lilly’s U.S. Patent No. 7,772,209 (“the ’209 Patent”) was valid and infringed under the doctrine of...more
Patent applications containing nucleic acid or protein sequences are required to include an electronic sequence listing using a required format and standard symbols. The United States Patent and Trademark Office (USPTO), in...more
On September 20, 2016, the U.S. Court of Appeals for the Federal Circuit issued an opinion affirming the summary judgement that Abbott’s U.S. Patent No. 5,344,915 (“the ’915 Patent”) was sufficiently supported by the written...more
10/10/2016
/ Anticipation ,
Appeals ,
Board of Patent Appeals ,
Inherent Disclosure Doctrine ,
Patent Applications ,
Patent Litigation ,
Patents ,
Prior Art ,
Priority Date Cutoff ,
Priority Patent Claims ,
Remand ,
Summary Judgment ,
Written Descriptions